Needlestick transmission of hepatitis C

JAMA

Volumn 287, Issue 18, 2002, Pages 2406-2413

  Sulkowski, Mark S ^a   Ray, Stuart C ^a   Thomas, David L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS C ANTIBODY; LAMIVUDINE; NELFINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; HEALTH CARE PERSONNEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; OCCUPATIONAL SAFETY; PATIENT COUNSELING; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS DIAGNOSIS; VIRUS TRANSMISSION;

EID: 0037042259     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.18.2406     Document Type: Article

References (101)

1. Updated U.S. Public Health Service Guidelines on the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis
2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
3. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study
4. A case-control study of HIV seroconversion in health care workers after percutaneous exposure
5. Hepatitis C virus infection in medical personnel after needlestick accident
6. Detection of hepatitis C virus markers and hepatitis C virus genomic-RNA after needlestick accidents
7. Hepatitis C in hospital employees with needlestick injuries
8. Hepatitis C virus infection in healthcare workers
9. Hepatitis C virus infection in healthcare workers
10. Lack of transmission of hepatitis C virus following needlestick accidents
11. Occupational transmission of HCV
12. Prevalence of hepatitis C antibodies in health-care workers
13. Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel
14. Transmissible agent in non-A, non-B hepatitis
15. Transmission of non-A, non-B hepatitis from man to chimpanzee
16. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
17. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus
18. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis
19. Systematic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus
20. Prospective reevaluation of risk factors in mother-to-child transmission of hepatitis C virus
21. Transmission of hepatitis C virus from mothers to infants
22. Mother-to-infant transmission of hepatitis C virus: A prospective study
23. Possible role of high-titer maternal viremia in perinatal transmission of hepatitis C virus
24. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers
25. Quantitative detection of hepatitis C virus RNA with a solidphase signal amplification method
26. Simultaneous infection with HIV and hepatitis C virus following occupational conjunctival blood exposure
27. Early events in hepatitis C virus infection of chimpanzees
28. Patterns and prevalence of hepatitis C virus infection in posttransfusion non-A, non-B hepatitis
29. Three different patterns of hepatitis C virus infection in chimpanzees
30. Persistence of viremia and the importance of longterm follow-up after acute hepatitis C infection
31. Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels
32. Reliability of polymerase chain reaction for detection of hepatitis C virus
33. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis
34. Transmission of hepatitis C via both erythrocyte and platelet transfusions from a single donor in serological windowphase of hepatitis C
35. Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA
36. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
37. Low levels of hepatitis C virus RNA in serum, plasma, and peripheral blood mononuclear cells of injecting drug users during long antibody-undetectable periods before seroconversion
38. The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus-positive hemophilic men undergoing HCV "seroreversion"
39. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay
40. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users
41. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients
42. Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b
43. Lack of seroconversion in a health care worker after polymerase chain reaction-documented acute hepatitis C resulting from a needlestick injury
44. Binding of hepatitis C virus to CD81
45. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor
46. The natural history of hepatitis C virus infection: Host, viral, and environmental factors
47. Chronic viral hepatitis and the human genome
48. Racial differences in HLA class II associations with hepatitis C virus outcomes
49. Influence of MHC class II genotype on outcome of infection with hepatitis C virus
50. Effect of immune globulin on the prevention of experimental hepatitis C virus infection
51. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization
52. Prevention of hepatitis C virus infection in chimpanzees by hyper-immune serum against the hypervariable region 1 of the envelope 2 protein
53. Natural recovery from acute hepatitis C virus infection by agammaglobulinemic twin children
54. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections
55. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the antiviral cell-mediated immune response
56. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia
57. +T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection
58. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection
59. Detection of type 2-like T-helper cells in hepatitis C virus infection
60. Detection of hepatitis C viral RNA
61. Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV
62. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
63. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection
64. Analysis of a successful immune response against hepatitis C virus
65. Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients
66. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons
67. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus
68. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants
69. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
70. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant
71. Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity
72. Longterm follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus
73. Hypervariable region 1 sequence stability during hepatitis C virus replication in chimpanzees
74. Analysis of successful immune responses in persons infected with hepatitis C virus
75. A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use
76. Factors associated with serum alanine transaminase activity in healthy subjects
77. Hepatitis C virus-associated fulminant hepatic failure
78. Evaluation of safety devices for preventing percutaneous injuries among health-care workers during phlebotomy procedures-Minneapolis-St. Paul, New York City, and San Francisco, 1993-1995
79. Rates of needle-stick injury caused by various devices in a university hospital
80. Occupational exposure to bloodborne pathogens: Final rule
81. Strategies and prospects for vaccination against the hepatitis C viruses
82. Hepatitis B immune globulin for accidental exposures among medical personnel
83. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B post-transfusion hepatitis
84. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients
85. Hepatitis C virus infection associated with administration of intravenous immune globulin: A cohort study
86. Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin
87. Acute hepatitis C transmitted by needlestick accident despite short duration interferon treatment
88. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
89. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C
90. Interferon-alpha in acute posttransfusion hepatitis C: A randomized, controlled trial
91. 2b treatment prevents chronicity in acute hepatitis C - A pilot study
92. A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C
93. Effects of interferon beta on non-A, non-B acute hepatitis
94. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment
95. Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis
96. Resolution of acute hepatitis C after therapy with natural beta interferon
97. The treatment of acute post-transfusion hepatitis C with recombinant interferon-alpha
98. Treatment of acute hepatitis C with interferon alfa-2b
99. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
100. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
101. Pegylated (40 kDa) interferon alfa-2a in combination with ribavirin